CN1017245B - 咪唑啉酮化合物的制备方法 - Google Patents

咪唑啉酮化合物的制备方法

Info

Publication number
CN1017245B
CN1017245B CN87107864A CN87107864A CN1017245B CN 1017245 B CN1017245 B CN 1017245B CN 87107864 A CN87107864 A CN 87107864A CN 87107864 A CN87107864 A CN 87107864A CN 1017245 B CN1017245 B CN 1017245B
Authority
CN
China
Prior art keywords
compound
gram
pyridyl
chemical formula
following chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN87107864A
Other languages
English (en)
Chinese (zh)
Other versions
CN87107864A (zh
Inventor
武田幹男
稻毛勝
和田博
玉木元
落合乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of CN87107864A publication Critical patent/CN87107864A/zh
Publication of CN1017245B publication Critical patent/CN1017245B/zh
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN87107864A 1986-11-14 1987-11-13 咪唑啉酮化合物的制备方法 Expired CN1017245B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP272655/86 1986-11-14
JP27265586 1986-11-14

Publications (2)

Publication Number Publication Date
CN87107864A CN87107864A (zh) 1988-08-31
CN1017245B true CN1017245B (zh) 1992-07-01

Family

ID=17516947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN87107864A Expired CN1017245B (zh) 1986-11-14 1987-11-13 咪唑啉酮化合物的制备方法

Country Status (16)

Country Link
US (1) US4886817A (enExample)
EP (1) EP0268229B1 (enExample)
JP (1) JPS63239281A (enExample)
KR (1) KR930002488B1 (enExample)
CN (1) CN1017245B (enExample)
AT (1) ATE78033T1 (enExample)
AU (1) AU597444B2 (enExample)
CA (1) CA1304376C (enExample)
DE (1) DE3780259T2 (enExample)
DK (1) DK597687A (enExample)
ES (1) ES2046193T3 (enExample)
FI (1) FI90869C (enExample)
GR (1) GR3005227T3 (enExample)
HU (1) HU198199B (enExample)
IE (1) IE61446B1 (enExample)
IL (1) IL84409A (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636439A (zh) * 2013-10-07 2016-06-01 先正达参股股份有限公司 除草化合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
GB9224144D0 (en) * 1992-11-18 1993-01-06 Erba Carlo Spa Phenyl-imidazolidinone derivatives and process for their preparation
JP3916092B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
US7129359B2 (en) 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
EP2027856A1 (en) * 2003-07-11 2009-02-25 Boehringer Ingelheim Vetmedica Gmbh Method of treating or preventing central nervous system disorders with compounds having selectivity benzodiazepine receptor
WO2005082054A2 (en) * 2004-02-26 2005-09-09 Sosei Co., Ltd. Combinations for the treatment of fungal infections
US7259174B2 (en) * 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
US20080070867A1 (en) * 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
NZ598548A (en) * 2006-08-15 2013-09-27 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
AU2013206248B2 (en) * 2008-06-27 2016-06-23 Xenon Pharmaceuticals Inc. Organic compounds
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CN102840229B (zh) * 2012-08-31 2015-11-18 中国舰船研究设计中心 可调心螺旋桨轴承装置
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ184081A (en) * 1976-06-01 1980-10-08 Velsicol Chemical Corp 1-thiazol-2-yl-1 3-imidazolidn-2-ones
US4604127A (en) * 1984-07-17 1986-08-05 Eli Lilly And Company Herbicidal pyridazinylimidazolidinone compounds
US4600430A (en) * 1985-02-22 1986-07-15 Eli Lilly And Company Pyridinylimidazolidinone compounds
AU568789B2 (en) * 1985-02-22 1988-01-07 Mitsui Toatsu Chemicals Inc. 3,3'-dinitrodiphenylether from m-dinitrobenzene
JPH06133172A (ja) * 1992-10-20 1994-05-13 Fujitsu General Ltd ファクシミリ装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636439A (zh) * 2013-10-07 2016-06-01 先正达参股股份有限公司 除草化合物

Also Published As

Publication number Publication date
KR930002488B1 (ko) 1993-04-02
DK597687A (da) 1988-05-15
IE61446B1 (en) 1994-11-02
DK597687D0 (da) 1987-11-13
EP0268229B1 (en) 1992-07-08
ES2046193T3 (es) 1994-02-01
HU198199B (en) 1989-08-28
EP0268229A3 (en) 1990-09-19
EP0268229A2 (en) 1988-05-25
KR880006231A (ko) 1988-07-22
DE3780259T2 (de) 1992-12-24
FI90869B (fi) 1993-12-31
DE3780259D1 (de) 1992-08-13
ATE78033T1 (de) 1992-07-15
IL84409A (en) 1991-12-15
AU597444B2 (en) 1990-05-31
HUT45983A (en) 1988-09-28
CA1304376C (en) 1992-06-30
CN87107864A (zh) 1988-08-31
FI874865L (fi) 1988-05-15
IL84409A0 (en) 1988-04-29
JPH05396B2 (enExample) 1993-01-05
IE873063L (en) 1988-05-14
AU8112587A (en) 1988-05-19
FI874865A0 (fi) 1987-11-04
FI90869C (fi) 1994-04-11
GR3005227T3 (enExample) 1993-05-24
JPS63239281A (ja) 1988-10-05
US4886817A (en) 1989-12-12

Similar Documents

Publication Publication Date Title
CN1052227C (zh) 作为粘结受体拮抗剂的噁唑烷酮,其制备方法和含它们的药物组合物
CN1176651C (zh) N-(3-苯并呋喃基)脲衍生物
CN1017245B (zh) 咪唑啉酮化合物的制备方法
CN1210268C (zh) ((环)烷基取代的)－γ－氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1845921A (zh) 金刚烷和氮杂双环－辛烷及壬烷衍生物、其制备方法及其作为dpp－iv抑制剂的用途
CN1094726A (zh) 噻唑烷二酮衍生物，它们的制备方法和用途
CN1044811A (zh) 杂环化合物
CN1031842A (zh) 新二唑
CN86106428A (zh) 抗肿瘤方法及其化合物
CN1031619C (zh) 噁唑烷酮衍生物用于制备药物
CN1182417A (zh) 吲哚衍生物
CN1023010C (zh) 4-杂五环-4-[n-(苯基)酰氨基]哌啶衍生物的制备方法
CN1051354A (zh) 取代环烷并[b]二氢吲哚-和-吲哚磺酰胺
CN1023219C (zh) 取代的咪唑衍生物的制备方法
CN1025334C (zh) 新的谷氨酸衍生物的制备方法
CN1017901B (zh) 抗精神病药稠环吡啶基哌嗪衍生物的制备方法
CN86108530A (zh) 苯基吖庚因的衍生物
CN1111634A (zh) 噻吩并噻嗪衍生物
CN1050380A (zh) 新的取代烷基哌啶及其作为胆固醇合成抑制剂的应用
CN1023479C (zh) 乙二胺的单酰胺衍生物的制备方法
CN1083472A (zh) 新的抗氧化剂
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法
CN1134415A (zh) 取代的苯磺酰脲和苯磺酰硫脲、其制备方法、制备药物制剂的用途和含有它们的药品
CN1224011A (zh) 新的杂环化合物,其制备方法以及含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee